Ester-E launch
This article was originally published in The Tan Sheet
Executive Summary
Zila's branded ingredient Ester-E will roll out to national retailers in the coming weeks, with consumer advertising beginning this month and radio promotions from national spokesperson Larry King. In the firm's fiscal fourth quarter, Zila "essentially sold all of the Ester-E that we could manufacture," CEO Doug Burkett said August 2. In fiscal 2005, the firm will add a second production line and double its 2004 marketing investment in the Ester brand with the goals of rapidly growing Ester-E and maintaining double-digit sales growth for Ester-C. In January, Zila said Ester-E could top $26 mil. in annual revenues (1"The Tan Sheet" Jan. 5, 2004, p. 13)...
You may also be interested in...
Zila results
Ester-C and Ester-E revenues rose 33% in the fourth quarter and 24% in fiscal year 2004 (ended July 31), the Phoenix, Ariz.-based firm reports Oct. 14. Zila ramped up production and marketing for the Ester brand by 34% in the fiscal year as the Ester-E line extension rolled out to retailers nationwide in the fourth quarter (1"The Tan Sheet" Aug. 9, 2004, In Brief). Zila's overall sales decreased 7% to $11.1 mil. in part due to discontinued saw palmetto products; the firm's fiscal 2004 sales increased 5% to $49.4 mil...
Zila Ester-E Set To Launch, May Eventually Top Ester-C In Sales
Zila is predicting its upcoming Ester-E branded vitamin E ingredient could surpass $26 mil. in annual revenues
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.